Herpes Simplex

AUTHOR INFORMATION Section 1 of 10    Click here to go to the top of this page Click here to go to the next section in this topic

Authored by Larry I Lutwick, MD, Director, Division of Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Professor, Department of Internal Medicine, State University of New York at Downstate

Coauthored by Meena Seenivasan, MD, Fellow, Department of Infectious Disease, State University of New York Health Science Center at Brooklyn

Larry I Lutwick, MD, is a member of the following medical societies: American College of Physicians, and Infectious Diseases Society of America

Edited by Thomas J Marrie, MD, Chair, Professor, Department of Medicine, Division of Infectious Diseases, University of Alberta College of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Charles V Sanders, MD, Edgar Hull Professor and Chairman, Department of Internal Medicine, Louisiana State University Health Sciences Center and School of Medicine; Eleftherios Mylonakis, MD, PhD, Clinical and Research Fellow in Infectious Disease, Howard Hughes Physician Postdoctoral Fellow, Department of Internal Medicine, Massachusetts General Hospital, Harvard University; and Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine, Director of Infectious Disease Fellowship, Chief, Division of Infectious Disease, Vice-Chair, Department of Internal Medicine, Winthrop University Hospital

¡@

Author's Email: Larry I Lutwick, MD ¡@ Click here to view conflict-of-interest information on the author of this topic
Editor's Email: Thomas J Marrie, MD

eMedicine Journal, December 21 2001, Volume 2, Number 12
¡@

INTRODUCTION ¡@

Background: Herpes simplex viruses (HSVs) are ubiquitous, extremely host-adapted pathogens that can cause a wide variety of illnesses. Two types exist: type 1 (HSV-1) and type 2 (HSV-2). Both are closely related but differ in epidemiology. HSV-1 is transmitted chiefly by contact with infected saliva, whereas HSV-2 is transmitted sexually or from a mother’s genital tract infection to her newborn.

Herpes simplex infections are asymptomatic in as many as 80% of patients, but symptomatic infections may be characterized by significant morbidity and recurrence. Moreover, infections can cause life-threatening complications, particularly in immunocompromised hosts.

HSV infection appears to have increased in prevalence worldwide in the last 2 decades, making it a major public health concern. The availability of effective chemotherapy underscores that the prompt recognition of the infection and early initiation of therapy are of utmost importance in the management of the disease.

¡@

Pathophysiology: HSV, belonging to the family Herpesviridae and to the subfamily Alphaherpesvirinae, is a double-stranded DNA virus characterized by the following unique biological properties:

¡@

Dissemination of infection occurs in people with impaired T-cell immunity such as organ transplant recipients and individuals with HIV-related disease.

Distribution of HSV is worldwide. Humans are the only natural reservoirs, and no vectors are involved in transmission. Because of latent infection, periodic reactivation, and virus shedding, endemicity is easily maintained in most human communities.

The mode of transmission is by close personal contact, and infection occurs via inoculation of virus into susceptible mucosal surfaces (eg, oropharynx, cervix, conjunctiva) or through small cracks in the skin. The virus is readily inactivated at room temperature and by drying; hence, aerosol and fomitic spread occur rarely.

¡@

Frequency:
¡@

Mortality/Morbidity: Morbidity and mortality of HSV infections are discussed in Complications. Overall, the mortality associated with herpes simplex infections is related to 3 situations: perinatal infection, encephalitis, and infection in the immunoincompetent host.

Race: No clear evidence indicates that the risk of infection with HSV relates directly to race.

Sex: Differences in frequency of genital HSV infections relate to sex only because infection relates to sexual activity, particularly without appropriate barrier protection.

Age: HSV-1 infections transmitted via saliva are common in children, although such primary herpes gingivostomatitis can be observed at any age. HSV-2 infections are clustered perinatally (from a maternal episode at delivery) and primarily once sexual activity begins. HSV-2 genital infections in children can be an indication of sexual abuse.

CLINICAL ¡@

History: The clinical course of the disease depends upon the age and immune status of the host, the anatomic site of involvement, and the antigenic type of the virus. While the primary infections caused by HSV-1 and HSV-2 are accompanied by systemic signs, longer duration of symptoms, and higher rate of complications, recurrent episodes are milder and shorter. Both HSV-1 and HSV-2 can cause similar genital and orofacial primary infections after contact with infectious secretions containing either HSV-1 (usually oral secretions) or HSV-2 (usually genital secretions).

Physical: This section addresses the physical examination of the herpetic lesion as it relates to primary and recurrent lesions of cutaneous or mucosal HSV infection. This can be related to either oral or genital infection.

Causes:

DIFFERENTIALS ¡@

Candidiasis
Chancroid
Hand-Foot-and-Mouth Disease
Syphilis
¡@


Other Problems to be Considered:

Oral ulcerative disease

Oral candidiasis
Hand-Foot-and-Mouth Disease
Aphthous Ulcers

Genital ulcerative disease

Syphilis
Chancroid

WORKUP ¡@

Lab Studies:
¡@

Imaging Studies:
¡@

Procedures:
¡@

TREATMENT ¡@

Medical Care:

Diet: A diet high in the amino acid lysine has been suggested as useful in preventing recurrences of HSV. Although viral yields in tissue culture are lower in a high lysine medium, replication still occurs. No objective clinical evidence exists to support this dietary manipulation.

MEDICATION ¡@

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
¡@

Drug Category: Antivirals -- Nucleoside analogs are phosphorylated initially by viral thymidine kinase to eventually form a nucleoside triphosphate. These molecules inhibit HSV polymerase with 30-50 times the potency of human alpha-DNA polymerase.

Drug Name
¡@
Acyclovir (Zovirax) -- Synthetic purine nucleoside analogue with activity against a number of herpesviruses, including herpes simplex and varicella-zoster. Highly selective for virus-infected cells because of its high affinity for viral thymidine kinase enzyme. This effect serves to concentrate acyclovir monophosphate into virus-infected cells. The monophosphate then is metabolized into the triphosphate active form by cellular kinases.
Double dose is suggested for herpes simplex proctitis or ocular infections. Ocular infections also can be treated with topical acyclovir. Oral suspension available (40 mg/mL).
Adult Dose First episode mucocutaneous herpes simplex: 200 mg PO 5 times daily or 400 mg tid for 7-10 d or until clinical resolution occurs
Recurrent genital herpes: 200 mg PO five times daily for 5 d
Chronic suppressive therapy: 400 mg bid or 200 mg 3-5 times daily; reevaluate after 1 y
Herpes simplex encephalitis: 10 mg/kg IV q8h for 10-14 d
Severe infection in immunocompromised host: 5-10 mg/kg IV q8h for 5-10 d
Pediatric Dose First episode mucocutaneous herpes simplex: 20-30 mg/kg/d in 5 divided doses for 7-10 d
Severe infections in immunocompromised children: 10 mg/kg/d IV q8h for 7 d
Herpes encephalitis: 20 mg/kg IV q8h for 10-14 d
Contraindications Documented hypersensitivity
Interactions Concomitant use of probenecid or zidovudine prolongs half-life and increases CNS toxicity
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Renal dysfunction (usually reversible) can occur during high-dose IV administration (primarily related to drug crystalluria); effect can be minimized by slow infusion and adequate hydration;
neurological symptoms, including lethargy, agitation, myoclonus, or seizures is observed in <1% of patients; appears to be dose-related phenomenon with increased risk with azotemia
Drug Name
¡@
Valacyclovir (Valtrex) -- Prodrug rapidly converted to the active drug acyclovir. More expensive but has a more convenient dosing regimen than acyclovir.
Adult Dose First episode herpes simplex: 1 g bid for 10 d, preferably beginning within 48 h of onset
Recurrent episode herpes simplex: 500 mg bid for 5 d beginning within 24 h of onset
Suppressive dosing for HSV: 500 mg to 1 g/d
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Probenecid, zidovudine, or cimetidine coadministration prolongs half-life and increases CNS toxicity of valacyclovir
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Caution in renal failure and coadministration of nephrotoxic drugs; associated with onset of hemolytic uremic syndrome
Drug Name
¡@
Famciclovir (Famvir) -- Prodrug that when biotransformed into active metabolite, penciclovir, may inhibit viral DNA synthesis/replication. Used against herpes simplex and varicella-zoster viruses.
Adult Dose Recurrent genital HSV: 125 mg bid for 5 d
Recurrent genital HSV in HIV-infected patients: 500 mg bid for 7 d
Suppression of frequent recurrence of genital HSV: 250 mg bid up to 12 mo
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Coadministration of probenecid or cimetidine may increase toxicity; coadministration increases bioavailability of digoxin
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Caution in renal failure or coadministration of nephrotoxic drugs; dosage adjustment in renal impairment recommended (half-life prolonged by 5-6 times if CrCl <20 mL/min)
FOLLOW-UP ¡@

Deterrence/Prevention:
¡@

Complications:
¡@

MISCELLANEOUS ¡@

Medical/Legal Pitfalls:
¡@

Special Concerns:
¡@

BIBLIOGRAPHY ¡@